HCA Healthcare Inc (HCA) PT Lowered to $525 at Jefferies

Jefferies analyst Brian Tanquilut lowered the price target on HCA Healthcare Inc (NYSE: HCA) to $525.00 (from $590.00) while maintaining a Buy rating.

The analyst commented, "The set-up for HCA into the Q1 print was tough as weather dragged on volumes, but the Street was all over the place in modeling its earnings impact. Sure enough, Jan ice storms in the South dragged on SS admits by 0.3%, weak respiratory revs drove another 0.7% drag, and the de-leveraging impact of the top line shortfall caused a rare EBITDA miss. We keep our Buy given upcoming SDP approvals, savings/productivity gains from "resiliency" program, and strong FCF."

You May Also Be Interested In

• Morgan Stanley Upgrades QIAGEN NV (QIA:GR) (QGEN) to Overweight
• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• Keurig Dr Pepper coffee chief to depart ahead of planned split